AEG‐1 promotes angiogenesis and may be a novel treatment target for tongue squamous cell carcinoma

Background The study explored the potential function of astrocyte elevated gene‐1 (AEG‐1) on angiogenesis in tongue squamous cell carcinoma (TSCC) in TSCC cell lines. Methods The different degrees of angiogenesis were detected in TSCC cell lines expressing different levels of AEG‐1 by chick chorioal...

Full description

Saved in:
Bibliographic Details
Published in:Oral diseases 2020-07, Vol.26 (5), p.876-884
Main Authors: Chen, Shan, Chen, Lei‐Hui, Niu, Yan‐Hong, Geng, Ning‐Bo, Feng, Chong‐Jin
Format: Article
Language:English
Subjects:
Angiogenesis
astrocyte elevated gene‐1
Chorioallantoic membrane
Dentistry
Enzyme-linked immunosorbent assay
Immunohistochemistry
microvessel density
Oral cancer
Squamous cell carcinoma
Therapeutic applications
Tongue
Tongue squamous cell carcinoma
Tumor cell lines
Vascular endothelial growth factor
Vascular endothelial growth factor receptors
vascular endothelial growth receptor factor 2
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The study explored the potential function of astrocyte elevated gene‐1 (AEG‐1) on angiogenesis in tongue squamous cell carcinoma (TSCC) in TSCC cell lines. Methods The different degrees of angiogenesis were detected in TSCC cell lines expressing different levels of AEG‐1 by chick chorioallantoic membrane (CAM) experimental model. Next, we established xenografts of different TSCC cell lines with different expression levels of AEG‐1 in nude mice and conducted immunohistochemistry to evaluate the expression of the angiogenesis‐associated factor, that is, vascular endothelial growth receptor factor 2 (VEGFR‐2) and microvessel density (MVD). Vascular endothelial growth factor (VEGF) was detected by ELISA. Results CAM assay showed that the number of vessels was significantly reduced in AEG‐1‐down um1 cell line (p 
ISSN:1354-523X
1601-0825
DOI:10.1111/odi.13300